# A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns

> **NCT06814717** · PHASE2 · RECRUITING · sponsor: **Neomatrix Therapeutics, Inc.** · enrollment: 6 (estimated)

## Conditions studied

- Thermal Burns

## Interventions

- **DRUG:** cP12

## Key facts

- **NCT ID:** NCT06814717
- **Lead sponsor:** Neomatrix Therapeutics, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06814717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06814717, "A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06814717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*